Our results should be validated in (1) a more physiologically relevant stroke model (e.g., ET-1-based MCA model) with relevant comorbidities, and (2) a chronic adaptation of the model, in which a histological endpoint can be obtained before transitioning into human applications. This evidence concerns the gene EDN1 and stroke disorder.